Completed
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
NCT01236391
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
- Locations
-
- Stanford University School of Medicine Stanford, California, United States
- Hackensack University Medical Center Hackensack, New Jersey, United States
- Cll Research and Treatment Program New Hyde Park, New York, United States
- New York Presbyterian Hospital/Cornell Medical Center New York, United States